Chlamydia Trachomatis Infections - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 38 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Chlamydia Trachomatis Infections - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Chlamydia Trachomatis Infections - Pipeline Review, H2 2014', provides an overview of the Chlamydia Trachomatis Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chlamydia Trachomatis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chlamydia Trachomatis Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chlamydia Trachomatis Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chlamydia Trachomatis Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chlamydia Trachomatis Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chlamydia Trachomatis Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chlamydia Trachomatis Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chlamydia Trachomatis Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Chlamydia Trachomatis Infections Overview 6
Therapeutics Development 7
Pipeline Products for Chlamydia Trachomatis Infections - Overview 7
Pipeline Products for Chlamydia Trachomatis Infections - Comparative Analysis 8
Chlamydia Trachomatis Infections - Therapeutics under Development by Companies 9
Chlamydia Trachomatis Infections - Therapeutics under Investigation by Universities/Institutes 10
Chlamydia Trachomatis Infections - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Chlamydia Trachomatis Infections - Products under Development by Companies 14
Chlamydia Trachomatis Infections - Products under Investigation by Universities/Institutes 15
Chlamydia Trachomatis Infections - Companies Involved in Therapeutics Development 16
ActivBiotics Pharma, LLC 16
Big DNA Ltd. 17
Foamix Pharmaceuticals Ltd. 18
Prokarium Ltd. 19
Chlamydia Trachomatis Infections - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
BDNA-003 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
chlamydia trachomatis vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
chlamydia vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
minocycline Gel - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
rifalazil - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Chlamydia Trachomatis Infections - Recent Pipeline Updates 35
Chlamydia Trachomatis Infections - Product Development Milestones 36
Featured News & Press Releases 36
Apr 26, 2010: Foamix is granted a fourth U.S. patent for OilGel, directed to pharmaceutical compositions and their dermatological, gynecological and ophthalmic applications 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38

List of Tables
Number of Products under Development for Chlamydia Trachomatis Infections, H2 2014 7
Number of Products under Development for Chlamydia Trachomatis Infections - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Comparative Analysis by Unknown Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Chlamydia Trachomatis Infections - Pipeline by ActivBiotics Pharma, LLC, H2 2014 16
Chlamydia Trachomatis Infections - Pipeline by Big DNA Ltd., H2 2014 17
Chlamydia Trachomatis Infections - Pipeline by Foamix Pharmaceuticals Ltd., H2 2014 18
Chlamydia Trachomatis Infections - Pipeline by Prokarium Ltd., H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 26
Number of Products by Stage and Molecule Type, H2 2014 28
Chlamydia Trachomatis Infections Therapeutics - Recent Pipeline Updates, H2 2014 35